JNJ Quote, Financials, Valuation and Earnings

Biogen has a net margin of 15.24% compared to Johnson & Johnson's net margin of 10.87%. Johnson & Johnson's return on equity of 19.98% beat Biogen's return on equity of 10.33%.

Johnson & Johnson has a consensus price target of $169.73, signalling upside risk potential of 9.96%. On the other hand Biogen has an analysts' consensus of $194.88 which suggests that it could grow by 63.41%. Given that Biogen has higher upside potential than Johnson & Johnson, analysts believe Biogen is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.490, which suggesting that the stock is 50.995% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.21%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Biogen quarterly revenues of $2.5B. Johnson & Johnson's net income of $3.4B is higher than Biogen's net income of $266.7M. Notably, Johnson & Johnson's price-to-earnings ratio is 26.66x while Biogen's PE ratio is 10.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.22x versus 1.80x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 15.24% compared to Johnson & Johnson's net margin of 23.56%. Johnson & Johnson's return on equity of 19.98% beat Gilead Sciences's return on equity of 2.5%.

Johnson & Johnson has a consensus price target of $169.73, signalling upside risk potential of 9.96%. On the other hand Gilead Sciences has an analysts' consensus of $112.50 which suggests that it could grow by 5.64%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Johnson & Johnson has a beta of 0.490, which suggesting that the stock is 50.995% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.21%. Gilead Sciences offers a yield of 2.91% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Johnson & Johnson's net income of $3.4B is higher than Gilead Sciences's net income of $1.8B. Notably, Johnson & Johnson's price-to-earnings ratio is 26.66x while Gilead Sciences's PE ratio is 287.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.22x versus 4.66x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 15.24% compared to Johnson & Johnson's net margin of 32.59%. Johnson & Johnson's return on equity of 19.98% beat Eli Lilly and's return on equity of 80.24%.

Johnson & Johnson has a consensus price target of $169.73, signalling upside risk potential of 9.96%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.89 which suggests that it could grow by 33.74%. Given that Eli Lilly and has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly and is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.490, which suggesting that the stock is 50.995% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.21%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Eli Lilly and quarterly revenues of $13.5B. Johnson & Johnson's net income of $3.4B is lower than Eli Lilly and's net income of $4.4B. Notably, Johnson & Johnson's price-to-earnings ratio is 26.66x while Eli Lilly and's PE ratio is 64.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.22x versus 15.14x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 15.24% compared to Johnson & Johnson's net margin of -117.16%. Johnson & Johnson's return on equity of 19.98% beat Moderna's return on equity of -29.09%.

Johnson & Johnson has a consensus price target of $169.73, signalling upside risk potential of 9.96%. On the other hand Moderna has an analysts' consensus of $51.31 which suggests that it could grow by 91.45%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.490, which suggesting that the stock is 50.995% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Johnson & Johnson has a quarterly dividend of $1.24 per share corresponding to a yield of 3.21%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.05% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $22.5B, which are larger than Moderna quarterly revenues of $956M. Johnson & Johnson's net income of $3.4B is higher than Moderna's net income of -$1.1B. Notably, Johnson & Johnson's price-to-earnings ratio is 26.66x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 4.22x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.